May 9 |
CG Oncology, Inc. reports Q1 results
|
May 9 |
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
|
May 6 |
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
|
May 3 |
CG Oncology reports data from Phase 3 bladder cancer study
|
May 3 |
CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
|
May 3 |
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
May 3 |
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
|
Apr 26 |
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
|
Apr 24 |
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
|
Mar 28 |
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
|